---
title: "Levodopa - Postencephalitic Parkinsonism"
sidebar: mydoc_sidebar
permalink: db01235-mesh-d010301-1.html
toc: false 
---


Path ID: `DB01235_MESH_D010301_1`
{% include image.html url="images/db01235-mesh-d010301-1.png" file="db01235-mesh-d010301-1.png" alt="db01235-mesh-d010301-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D007980 | levodopa | Drug |
| MESH:D004295 | Dihydroxyphenylalanine | ChemicalSubstance |
| UniProt:P35462 | D(3) dopamine receptor | Protein |
| GO:0001963 | synaptic transmission, dopaminergic | BiologicalProcess |
| MESH:D010301 | Postencephalitic parkinsonism | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Levodopa | HAS METABOLITE | Dihydroxyphenylalanine |
| Dihydroxyphenylalanine | POSITIVELY REGULATES | D(3) Dopamine Receptor |
| D(3) Dopamine Receptor | POSITIVELY REGULATES | Synaptic Transmission, Dopaminergic |
| Synaptic Transmission, Dopaminergic | NEGATIVELY CORRELATED WITH | Postencephalitic Parkinsonism |
|---------|-----------|---------|

Comment: It's been debated whether the side effects of this drug is worth it when used for treating Parkinson's (https://en.wikipedia.org/wiki/Dopamine_agonist#History).

Reference: 
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1009/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1009/)
  - [https://en.wikipedia.org/wiki/L-DOPA#Medical_use](https://en.wikipedia.org/wiki/L-DOPA#Medical_use)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/6047#section=Mechanism-of-Action](https://pubchem.ncbi.nlm.nih.gov/compound/6047#section=Mechanism-of-Action)
